Maxime Frelaut
@mfrelaut.bsky.social
Medical Oncologist at Gustave Roussy, France. Head of the geriatric oncology unit. Interested in geriatric, thoracic and GU oncology.
Reposted by Maxime Frelaut
A new epigenetic clock —DNAmIC—outperforms others for identifying risk of all-cause mortality, and linked with lifestyle and immune system factors @nataging.nature.com
www.nature.com/articles/s43...
www.nature.com/articles/s43...
A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors - Nature Aging
Fuentealba and colleagues build and validate a DNA methylation clock of intrinsic capacity (IC) to bridge resource-intensive clinical assessments of IC with molecular readouts of aging, highlighting s...
www.nature.com
June 4, 2025 at 2:34 PM
A new epigenetic clock —DNAmIC—outperforms others for identifying risk of all-cause mortality, and linked with lifestyle and immune system factors @nataging.nature.com
www.nature.com/articles/s43...
www.nature.com/articles/s43...
Reposted by Maxime Frelaut
On #LungCancerConsidered this week, @narjustflorezmd.bsky.social & Dr. Mihaela Aldea talk about RET-positive NSCLC: diagnostic hurdles, treatment choices & more!
🎧 Tune in: bit.ly/TL25RET
#TexasLung25 #NSCLC
🎧 Tune in: bit.ly/TL25RET
#TexasLung25 #NSCLC
What You Should Know About RET-Positive NSCLC: Live from TexasLung25 | IASLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about th ...
bit.ly
April 29, 2025 at 8:42 PM
On #LungCancerConsidered this week, @narjustflorezmd.bsky.social & Dr. Mihaela Aldea talk about RET-positive NSCLC: diagnostic hurdles, treatment choices & more!
🎧 Tune in: bit.ly/TL25RET
#TexasLung25 #NSCLC
🎧 Tune in: bit.ly/TL25RET
#TexasLung25 #NSCLC
Reposted by Maxime Frelaut
Creating a Mammography Conversation Aid for Shared Decision-Making Between Clinicians and Women Aged 75 and Older. #geriatrics #medsky agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
April 24, 2025 at 9:59 PM
Creating a Mammography Conversation Aid for Shared Decision-Making Between Clinicians and Women Aged 75 and Older. #geriatrics #medsky agsjournals.onlinelibrary.wiley.com/doi/10.1111/...
📢 Webinaire HOT d'OG @SOFOG @DIALOG
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
April 7, 2025 at 11:19 AM
📢 Webinaire HOT d'OG @SOFOG @DIALOG
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
🧠 Machine Learning & modèle pronostique présenté par Étienne Audureau
📅 19 mai | 18h-19h
📄 D’après sa publication JCO janv 2025: pubmed.ncbi.nlm.nih.gov/39854651/
🔓 Gratuit sur inscription : lien ci-dessous
👉rejoignez-nous ! #gerionc #Oncogériatrie
For Oncology Residents
📅 ESMO Preceptorship on Cancer Care in Elderly Patients – May 8-9, 2025, Lugano
✅ Present your own geriatric oncology case
✅ Network with experts & peers across Europe
🔗 Apply now (deadline: March 27)
#Oncology #GeriatricOncology #ESMO #GeriOnc
📅 ESMO Preceptorship on Cancer Care in Elderly Patients – May 8-9, 2025, Lugano
✅ Present your own geriatric oncology case
✅ Network with experts & peers across Europe
🔗 Apply now (deadline: March 27)
#Oncology #GeriatricOncology #ESMO #GeriOnc
ESMO Preceptorship on Cancer Care in Elderly Patients 2025 Lugano
8-9 May 2025
www.esmo.org
March 18, 2025 at 3:33 PM
For Oncology Residents
📅 ESMO Preceptorship on Cancer Care in Elderly Patients – May 8-9, 2025, Lugano
✅ Present your own geriatric oncology case
✅ Network with experts & peers across Europe
🔗 Apply now (deadline: March 27)
#Oncology #GeriatricOncology #ESMO #GeriOnc
📅 ESMO Preceptorship on Cancer Care in Elderly Patients – May 8-9, 2025, Lugano
✅ Present your own geriatric oncology case
✅ Network with experts & peers across Europe
🔗 Apply now (deadline: March 27)
#Oncology #GeriatricOncology #ESMO #GeriOnc
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
February 15, 2025 at 11:23 PM
Honored to present CABOLD study design at #ASCOGU25!
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
A prospective cohort assessing the feasibility of cabozantinib + nivolumab in m+ ccRCC for 70+ patients :
✅ Geriatric data at baseline & follow-up
✅ Enhanced monitoring
✅ Plasma monitoring of Cabo
#ASCOGU25 #KidneyCancer #OncoGeriatrics
Reposted by Maxime Frelaut
Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG).
www.thelancet.com/journals/lan...
@thelancet.bsky.social @thelancetoncol.bsky.social @siogorg.bsky.social #GeriOnc
www.thelancet.com/journals/lan...
@thelancet.bsky.social @thelancetoncol.bsky.social @siogorg.bsky.social #GeriOnc
February 5, 2025 at 2:17 AM
Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG).
www.thelancet.com/journals/lan...
@thelancet.bsky.social @thelancetoncol.bsky.social @siogorg.bsky.social #GeriOnc
www.thelancet.com/journals/lan...
@thelancet.bsky.social @thelancetoncol.bsky.social @siogorg.bsky.social #GeriOnc
At #MAO2025, Dr. Camille Chakiba presented the PRIORITY study on cancer patients’ care goals:
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
January 31, 2025 at 2:02 PM
At #MAO2025, Dr. Camille Chakiba presented the PRIORITY study on cancer patients’ care goals:
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
📌 Key finding: Patients 70+ prioritize treatment efficacy, while oncologists emphasize toxicity risks more than patients themselves.
💡 Takeaway: Goals must be discussed case by case!
#Oncogeriatrics
📢 #MAO2025 | Chemo + IO in metastatic NSCLC for ≥65:
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
January 31, 2025 at 1:44 PM
📢 #MAO2025 | Chemo + IO in metastatic NSCLC for ≥65:
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
🔹 Meta-analysis (Dr. Emeline Orillard)
✅ Improved OS & PFS with IO in ≥65
❗ No significant benefit after 75 (small sample size)
📊 Update ongoing + need for raw data sharing.
#NSCLC #Immunotherapy #GeriatricOncology #MAO2025
🔬 ADC & elderly breast cancer patients 👵🎗️
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
January 30, 2025 at 4:20 PM
🔬 ADC & elderly breast cancer patients 👵🎗️
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
At #MAO2025, experts highlighted:
✅ Efficacy signal in 65+ but limited data for older patients
⚠️ More toxicity & treatment discontinuation
🚀 Include elderly in innovation but with vigilance
#Oncogeriatrics #BreastCancer #ADC #CancerResearch
📢 Capucine Baldini at MAO 2025:
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
January 30, 2025 at 9:44 AM
📢 Capucine Baldini at MAO 2025:
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
• ✅ No loss of efficacy of immunotherapy in older patients
• ❓ Immunosenescence impact? Still unclear
• 🔍 Need for prospective clinical & translational data
#MAO2025 #OncoGeriatrics #Immunotherapy
Reposted by Maxime Frelaut
9.5% MET and 7.9% EGFR detected in pts w lung SqCC with no smoking history.
Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease.
#lcsm
Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease.
#lcsm
Biomarker testing can help identify actionable mutations in patients with SqNSCLC, especially in those without a history of smoking. Testing is not performed consistently in this setting. #LCSM #lungcancer
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking
Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung c…
www.sciencedirect.com
January 19, 2025 at 4:48 PM
9.5% MET and 7.9% EGFR detected in pts w lung SqCC with no smoking history.
Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease.
#lcsm
Important to improve testing in this group. We are finding more of this with reflex testing in early stage disease.
#lcsm
🚨 Excited to share our work : "Systemic treatment among frail older patients with cancer".
✅ 3-month OS 81.8% when guided by geriatric assessments.
⚠️ Loss of ADL and cumulative frailty factors associated with poorer survival
🔗https://www.geriatriconcology.net/article/S1879-4068(24)00450-8/abstract
✅ 3-month OS 81.8% when guided by geriatric assessments.
⚠️ Loss of ADL and cumulative frailty factors associated with poorer survival
🔗https://www.geriatriconcology.net/article/S1879-4068(24)00450-8/abstract
Systemic treatment among frail older patients with cancer: An observational cohort
In the past, certain oncological therapies were not offered to frail older patients. However, the advancement of geriatric oncology, tailored chemotherapy regimens, the introduction of new treatments, and the optimization of supportive care have contributed to enhancing the therapeutic margin. We aimed to evaluate the benefit of systemic treatment among older adults by assessing the three-month survival of older frail patients with metastatic cancer.
www.geriatriconcology.net
December 30, 2024 at 9:40 AM
🚨 Excited to share our work : "Systemic treatment among frail older patients with cancer".
✅ 3-month OS 81.8% when guided by geriatric assessments.
⚠️ Loss of ADL and cumulative frailty factors associated with poorer survival
🔗https://www.geriatriconcology.net/article/S1879-4068(24)00450-8/abstract
✅ 3-month OS 81.8% when guided by geriatric assessments.
⚠️ Loss of ADL and cumulative frailty factors associated with poorer survival
🔗https://www.geriatriconcology.net/article/S1879-4068(24)00450-8/abstract
Reposted by Maxime Frelaut
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 26, 2024 at 8:55 PM
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Reposted by Maxime Frelaut
Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung #Cancer in Routine Clinical Practice: A Nationwide Cohort Study.
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
December 22, 2024 at 9:42 PM
Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung #Cancer in Routine Clinical Practice: A Nationwide Cohort Study.
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
Reposted by Maxime Frelaut
At #SABCS24 LBA session - an EBCTCG meta-analysis explored immediate vs deferral surgery in women 70+ with operable breast cancer
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
December 11, 2024 at 12:11 AM
At #SABCS24 LBA session - an EBCTCG meta-analysis explored immediate vs deferral surgery in women 70+ with operable breast cancer
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
Reposted by Maxime Frelaut
Can gender & genetics impact alectinib tox? @jtoonline.bsky.social
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer
Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.
www.jto.org
December 9, 2024 at 8:46 PM
Can gender & genetics impact alectinib tox? @jtoonline.bsky.social
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...